Searched for
NOVARTIS HEALTHCARE
India needs to remain attractive for innovation-led investment: Judith Love, NovartisWith an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...
Avammune’s big bet: Why the future of cancer treatment may come in a pillAs global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...
Molecule glue drugs shake up cancer care, draw big moneyHarvard-born idea doubles survival in trials, triggers pharma frenzy as cos race to target 'undruggable' proteins with next-gen glue therap...
Citi sees India IPOs hitting fresh records despite challengesIndian initial public offerings are poised for a strong comeback in the latter half of the year. Citigroup anticipates deal volumes to meet...
Novartis sharpening India strategy as a pure-play innovatorNovartis India country president and managing director Amitabh Dube said India is gradually moving beyond its traditional role as a clinica...
DeepMind CEO Demis Hassabis’ Isomorphic Labs raises $2.1 billion led by Thrive CapitalAI-driven drug discovery firm Isomorphic Labs secured a massive $2.1 billion in Series B funding. This capital will fuel the expansion of t...
Google’s Isomorphic Labs to raise over $2 billion in new fundingAlphabet's AI drug discovery firm, Isomorphic Labs, is reportedly close to securing over $2 billion in new funding, led by Thrive Capital. ...
Global Markets | European shares subdued as US-Iran talks stall; corporate earnings on tapEuropean shares were muted on Tuesday as investors braced for a week packed with central bank meetings and corporate earnings, while weighi...
Anthropic appoints Indian-origin Novartis CEO Vas Narasimhan to its boardAnthropic’s Long-Term Benefit Trust is an independent governance body, designed to insulate key decisions as it scales its frontier AI syst...
Novartis exits India arm, ChrysCapital-led group buys 70.68% stake for ₹1,446 croreSwiss drugmaker Novartis AG is selling its 70.68% stake in its Indian unit for Rs 1,446 crore to a consortium led by ChrysCapital. This div...
ChrysCapital, two others launch open offer for Novartis IndiaA consortium including WaveRise Investments, ChrysCapital, and Two Infinity Partners is set to acquire a significant stake in Novartis Indi...
PE firms queue up for Novartis' Indian armThe PE firms are up against Dr Reddy's, which has an alliance with Novartis for marketing some of its off-patent products and is also expec...
Novartis puts its India-listed entity for up for saleThe strategic review will include an assessment of the 70.68% shareholding of Novartis AG in Novartis India. Novartis said there is no assu...
JB Pharma acquires trademark licenses, distribution rights of Novartis eye care portfolio in India for Rs 1089 croreJB will pay Rs 964 crore for the portfolio licensing agreement with Novartis Innovative Therapies AG which the company said is "perpetual i...
Novartis India appoints Milan Paleja as vice chairman and MDPaleja is currently country president at Novartis in India and is also responsible for the pharmaceuticals business in the country. He is a...
Novartis Healthcare launches psoriasis treatment drug in IndiaNovartis Healthcare has launched secukinumab, used for the treatment of plaque psoriasis in adult patients, in India. The company has launc...
GSK Pharma completes deal with Novartis HealthcareDrug firm GlaxoSmithKline Pharmaceuticals has acquired Novartis' vaccines business and divested its marketed oncology portfolio to Novartis...
Competition Commission of India clears Novartis-GlaxoSmithKline pharma dealThe multi-layered deal involves UK-based GlaxoSmithKline acquiring Novartis's vaccine biz, while latter would purchase GSK's cancer drugs p...
GlaxoSmithKline Consumer Healthcare Ltd India-Novartis deal won't affect business in IndiaGlaxoSmithKline Consumer Healthcare today said the global deal between GlaxoSmithKline Plc and Novartis won't affect its business in India.
- Nestle buys baby food biz off Novartis
Swiss food giant Nestle is buying the Gerber baby food business off pharma major Novartis for $5.5 bn.